- Home
- PBFS vs CADL Comparison
PBFS vs CADL Comparison
Compare PBFS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- CADL
- Stock Information
- Founded
- PBFS 1889
- CADL 1999
- Country
- PBFS United States
- CADL United States
- Employees
- PBFS N/A
- CADL N/A
- Industry
- PBFS Banks
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- CADL Health Care
- Exchange
- PBFS Nasdaq
- CADL Nasdaq
- Market Cap
- PBFS 287.0M
- CADL 252.0M
- IPO Year
- PBFS N/A
- CADL 2021
- Fundamental
- Price
- PBFS $12.50
- CADL $5.12
- Analyst Decision
- PBFS
- CADL Strong Buy
- Analyst Count
- PBFS 0
- CADL 5
- Target Price
- PBFS N/A
- CADL $21.40
- AVG Volume (30 Days)
- PBFS 35.5K
- CADL 923.9K
- Earning Date
- PBFS 05-09-2025
- CADL 08-12-2025
- Dividend Yield
- PBFS N/A
- CADL N/A
- EPS Growth
- PBFS 27.31
- CADL N/A
- EPS
- PBFS 0.80
- CADL N/A
- Revenue
- PBFS $88,641,000.00
- CADL N/A
- Revenue This Year
- PBFS N/A
- CADL N/A
- Revenue Next Year
- PBFS N/A
- CADL N/A
- P/E Ratio
- PBFS $15.63
- CADL N/A
- Revenue Growth
- PBFS 21.19
- CADL N/A
- 52 Week Low
- PBFS $10.07
- CADL $3.79
- 52 Week High
- PBFS $12.65
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- PBFS 66.94
- CADL 48.58
- Support Level
- PBFS $11.89
- CADL $4.73
- Resistance Level
- PBFS $12.65
- CADL $5.24
- Average True Range (ATR)
- PBFS 0.37
- CADL 0.29
- MACD
- PBFS 0.07
- CADL 0.00
- Stochastic Oscillator
- PBFS 88.00
- CADL 64.92
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.